Serum tryptophan, kynurenine, and neopterin in patients with guillain-barre-syndrome (GBS) and multiple sclerosis (MS)

Advances in Experimental Medicine and Biology

Volumn 398, Issue , 1996, Pages 183-187

  Rudzite, V ^a   Berzinsh, J ^b   Grivane, I ^b   Fuchs, D ^c   Baier Bitterlich, G ^c   Wachter, H ^c  

^a UNIVERSITY OF LATVIA   (Latvia)

^b RIGA STRADINS UNIVERSITY   (Latvia)

^c UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BIOPTERIN; DRUG DERIVATIVE; KYNURENINE; NEOPTERIN; TRYPTOPHAN;

ARTICLE; BLOOD; HUMAN; MULTIPLE SCLEROSIS; POLYRADICULONEUROPATHY; REFERENCE VALUE; TIME;

BIOPTERIN; HUMANS; KYNURENINE; MULTIPLE SCLEROSIS; NEOPTERIN; POLYRADICULONEUROPATHY; REFERENCE VALUES; TIME FACTORS; TRYPTOPHAN;

EID: 0030333496     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4613-0381-7_30     Document Type: Article

References (25)

1. Bansil S., Mithen F.A., Singhal B.S., Cook S.D., Rehewsky-Kochan Ch., 1992, Elevated neopterin levels in Guillain-Barre syndrome. Arch. Neurology, 49 : 1277.
2. Brown R.R., Borden E.C., Sondel P.M., Lee C.M., 1987, Effect of interferons and interleukin-2 on tryptophan metabolism in humans. In: Progress in Tryptophan and Serotonin research 1986, Bender D.A., Joseph M.H., Kochen W., Steinhart H. Eds., Walter de Gruyter, Berlin-New York, p. 19-26.
3. Demisch L., Proescholdt M., Ott M., Engelhardt W., Baas H., Enzensberger W., Fischer P.A., 1994, CSF tryptophan in inflammatory neurological diseases. In: L-tryptophan. Current Prospects in Medicine and Drug Safety, Kochen W. and Steinhart H. Eds., Walter de Gruyter, Berlin- New York, p. 139-149.
4. Dencla W., Dewey M.K., 1967, The determination of tryptophan in plasma, liver and urine, J. Lab. Clin. Med., 69: 160.
5. Donaghy M., 1993, Acute idiophatic polyneuritis. In: Brain Diseases of Nervous System, Walton J. Eds., Oxford University Press, p.599-603.
6. Ebers G.C., 1995, Multiple Sclerosis. MS slide lecture series, Produced as an educational service from Schering A.G., Canada, p. 21-23.
7. Eccleston E.G., 1973, A method for estimation of free and total acid-soluble plasma tryptophan using an ultrafiltration technique, Clin.Chim.Acta, 48: 269.
8. Evans S.W., Whicher J.T., 1993, The cytokines: physiological and pathophysiological aspects, Advances in Clin. Chemistry, 30 : 1.
9. Hartung H.P., Jung S., Stoll G., Zielasek J., Schmidt B., Archelos J.J., Toyka K.V., 1992, Inflammatory mediators in demyelinating disorders of the CNS and PNS, J.Neuroimmunology, 40; 197.
10. Honavar M., Thanakan J.K.J., Hugher R.A.C., Leibovitz S., Winer J.B., 1991, A clinicopathological study of the Guillain-Barre syndrome. Brain, 114: 1245.
11. Joseph M.H., Risby D., 1975, The determination of kynurenine in plasma, Clin. Chim.Acta, 63: 197.
12. Mc Farlin D.E., 1990, Immunological parametrs in Guillain-Barre syndrome, Annals of Neurology, Supplement to 27 : 25.
13. Milovanovic D.D., Stevatovic H.L., 1992, Cerebrospinal fluid serotonin and 5-hydroxyindolacetic acid and plasma tryptophan in demyelinating diseases and some neurological disorders. In: Advances in Tryptophan Research 1992, Ishigure I., Kido R., Nagatsu Y., Nagamura Y., Ohta Y. Eds., Fujita Health University Press, Toyoake, p. 101-106.
14. Murray D.P., 1993, Impaired mobility: Guillain -Barre syndrome, J.Neuroscience and Nursing, 25 : 100.
15. Opieñska-Blauth J., Chareziñski M., Berbeč H., 1964, Tryptophan in erytrocytes and plasma in man and some animals, Acta Biochemica Polonica, 11 : 147.
16. Ramsohoff R.M., Tuohy V., Lehman P., 1994, The immunology of multiple sclerosis : new intricacies and new insights, Current Opinion in Neurology, 7 : 242.
17. Rieckmann P., Albrecht M., Kitze B., Weber T., Tumani H., Brooks A., Lüer W., Helvig A., Poser S., 1995, Tumor necrosis factor-α messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity, Annals of Neurology, 37 : 82.
18. Rosenblum M.G., Donato N.J., 1989, Tumor necrosis factor-α : a multifaced peptide hormone, CRC Crit. Rev. Immunol., 9: 21.
19. Stoll G., Jung S., Jander S., Meide P., Hartung H.P., 1993, Tumor necrosis factor -α in immunomediated demyelination and Wallerain degeneration of rat peripheral nervous system, J.Neuroimmunology, 45: 175.
20. Spies J.R., Chambers D.C., 1949, Chemical determination of tryptophan. Study of color formation reaction of tryptophan, p-dimethylaminobenzaldehide and sodium nitrite in sulfuric acid solution, Analytical Chemistry, 20: 30.
21. Wachter H., Fuchs D., Hausen A., Reibnegger G., Werner E.R., 1989, Neopterin as a marker for activation of cellular immunity: immunologic basis and clinical application, Advances in Clinical Chemistry, 27: 81.
22. Wachter H., Fuchs D., Hausen A., Reibnegger G., Weiss G., Werner E.R., Werner- Felmayer G., 1992, Neopterin: Biochemistry - Methods - Clinical Application, Walter de Gruyter, Berlin- New York.
23. Werner E.R., Werner-Felmayer G., Fuchs D., Hausen A., Reibnegger G., Wachter H., 1991, Relationships between pteridine synthesis and tryptophan degradation, Advances in Experimental Medicine and Biology, 294 : 177.
24. Weber E., 1957, Grundriss der biologischen Statistik für Naturwissenschaftler, Landvirte und Mediziner, Gustav Fischer Verlag, Jena.
25. Whicher J.T., Evans S.W., 1990, Cytokines in diseasee, Clin. Chem., 36: 1269.